LifeArc Announces Network of Innovation Hubs for Gene Therapies
As part of the Rare Disease Translational Challenge, LifeArc is leading the network of Innovation Hubs for Gene Therapies
London, 27th January 2022 - LifeArc, a leading medical research charity, today announced the launch of a network of Innovation Hubs for Gene Therapies, as part of the Rare Disease Translational Challenge.
The network will bring together leading experts from academia, industry, the NHS and patient groups to accelerate the development and delivery of gene therapies for rare diseases.
Gene therapies are a promising new approach to treating rare diseases caused by genetic defects. They involve delivering a functional copy of a gene to a patient's cells, which can then produce the protein that the patient is missing or has a faulty version of.
However, developing gene therapies is complex and expensive, and there are a number of barriers to their widespread use. The Innovation Hubs will address these barriers by providing researchers with access to the resources and expertise they need to translate their research into clinical trials and ultimately into new treatments for patients.
The network will be led by LifeArc's Senior Business Manager, Kieran Hudson. Kieran has over 15 years' experience in the pharmaceutical industry, and he has a deep understanding of the challenges and opportunities involved in developing gene therapies.
Kieran said: "I am delighted to be leading this exciting new initiative. Gene therapies have the potential to transform the lives of patients with rare diseases, and I am confident that the Innovation Hubs will play a vital role in accelerating their development and delivery."
The other members of the LifeArc team involved in the project are Laura Stennett PhD, Rachael Brooker, and Anji Miller PhD CLP RTTP.
If you are an MRC researcher and would like to find out more about the scheme, please get in touch with your LifeArc contact.
The online seminar series will consist of 4 sessions:
- Seminar 1 - The Development Pathway for Gene and Cell Therapies
- Seminar 2 - Gene and Cell Therapy Product Development
- Seminar 3 - Clinical Trial Design and Conduct for Gene and Cell Therapies
- Seminar 4 - Regulatory Considerations for Gene and Cell Therapies
For more information, please visit the LifeArc website.
Comments